稳定性 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-06. Anything still debated is marked as such rather than presented as settled.
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
| 性质 | 取值 | 备注 |
|---|---|---|
| 外观 | 白色至类白色冻干粉 | 常见形态 |
| 溶解性 | 易溶于水与水性缓冲液 | 多肽类通性 |
| 典型储存温度 | -20°C 或更低 | 干燥避光 |
| 常用纯度方法 | 反相高效液相色谱 | 214 nm 紫外检测 |
| 常用分子量确认 | 质谱 | 电喷雾或激光解吸 |
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
== Historical uses == In 1959, the combination of phenoperidine and haloperidol was first used in Europe in anesthesia to induce a detached, pain free state called neuroleptic analgesia; the use of that mixture boomed in early 1960s but was overtaken by the combination of fentanyl and droperidol, which was widely used through the 1980s. These combination approaches were not adopted in the US.
Risk of developing CJD increases with age. CJD incidence was 3.5 cases per million among those over 50 years of age between 1979 and 2017. Approximately 85% of CJD cases are sporadic, and 10–15% of CJD cases are due to inherited mutations of the prion protein gene. CJD deaths and age-adjusted death rate in the United States indicate an increasing trend in the number of deaths between 1979 and 2017. Although not fully understood, additional information suggests that CJD rates in nonwhite groups are lower than in whites. While the mean onset is approximately 67 years of age, cases of sCJD have been reported as young as 17 years and over 80 years of age. Mental capabilities rapidly deteriorate and the average amount of time from onset of symptoms to death is 7 to 9 months. According to a 2020 systematic review on the international epidemiology of CJD:
{\displaystyle {\begin{cases}{\ce {^{235}_{92}U + ^{1}_{0}n -> ^{236m}_{92}U ->[][120 \ {\ce {ns}}] ^{236}_{92}U + \gamma}}\\{\ce {^{236}_{92}U + ^{1}_{0}n -> ^{237}_{92}U ->[\beta^-][6.75 \ {\ce {d}}] ^{237}_{93}Np}}\end{cases}}}
Sources: en.wikipedia.org
== Goals == The goals of the BRSD are the separation of church and state, the democratization of the church, the political neutrality of the church, non-denominational schools, an end of the chaplaincy and for the church to work for peace and international understanding.
From the records of St. Francis' physical ailments and symptoms, Edward Frederick Hartung concluded in 1935 that St. Francis had an eye ailment known as trachoma and quartan malaria. Quartan malaria infects the liver, spleen, and stomach, causing the victim intense pain. One complication of quartan malaria is known as purpura, a purple hemorrhage of blood into the skin. According to Hartung "If this were the case of St. Francis, he would have been afflicted by ecchymoses, an exceedingly large purpura. The purple spots of blood may have been punctured while in the wilderness and there appear as an open wound like that of Christ." A later medical hypothesis was proposed in 1987 to explain the wounds, it claimed that St. Francis may have contracted leprosy.
The subscripts simply refer to the respective nuclides, i.e. NA is the number of nuclides of type A; NA0 is the initial number of nuclides of type A; λA is the decay constant for A – and similarly for nuclide B. Solving this equation for NB gives:
Both lepa1 and lepa2 have two characteristic cysteine residues which predict the formation of a disulfide bond in Lep, which is a pre-equisite for this 3D configuration and bioactivity of human LEP. The models suggest that the bonding of lepa2 might be different from lepa1. There are several differences between the 3D structures of lepa1 and lepa2; e.g. α-helix 5 is considerable shorter in lepa1 than lepa2. Furthermore, α-helix 1 for lepa2 appears to be split by a short-disordered region, and may therefore have a poorer affinity. However, considering that it is a predicted model based upon the structure mask of human LEP, the significance of these putative conformational adjustments remains to be tested. The importance of the conserved tertiary structure of Lep is most likely explained by requirements for specific LepR-binding affinity and is constrained by the structure of the receptor-binding pocket. This might also explain some of the results from studies on teleost using heterologous mammalian Lep. E.g. treatment with the mammalian hormone caused an anorexic effect in goldfish (Carassius auratus) and green sunfish (Lepomis cyanellus), but not in Coho salmon (Oncorhynchus kisutch), channel catfish (Ictalurus punctatus) and green sunfish. These contradicting results have been explained by the relatively large differences in amino acid sequences observed between mammals and fish. Rønnestad and colleagues recently detected five isoforms of the leptin receptor (lepr) that have differences in 3'-end of the mRNA sequence.
Sources: en.wikipedia.org
多肽在反相柱上按疏水性差异分离，能有效区分主峰、缺失序列片段与氧化产物。配合紫外检测可获得可量化的纯度百分比，是肽类分析的常规手段。
一般建议密封、避光、干燥，并在 -20°C 或更低温度下存放。温度波动和湿气是主要风险，长期存放应避免反复开启容器。
没有统一答案，取决于缓冲液、浓度、pH 与储存温度。多数做法是冷藏并在数天至数周内用完，具体期限需要通过稳定性实验确认。
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.